Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy

Completed · Phase 1/Phase 2

Conditions studied: Polypoidal Choroidal Vasculopathy

In brief

This Phase I/II safety study is designed to investigate the safety and efficacy of ranibizumab (Lucentis) in the treatment of polypoidal choroidal vasculopathy (PCV), a potentially blinding eye disease that involves the growth of tiny, abnormal blood vessels under the retina. These abnormal blood vessels can bleed or leak fluid, causing disruption of normal retinal function and vision loss. Ranibizumab is a drug that is FDA-approved for the treatment of wet age-related macular degeneration (AMD) and is injected directly into the eye. Given the efficacy of ranibizumab in the treatment of wet AMD, and the postulated similarity between the disease mechanisms involved in both wet AMD and PCV, we believe ranibizumab will have a beneficial effect on visual function in patients with PCV.

Key facts

Study ID

NCT00837330

Run by

Southeast Retina Center, Georgia

People needed

20

Starts

2006-05-01

Expected to finish

2010-12-01

Last updated by the study team

2019-04-16

Who can join

Age: 35 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age >35 years
• Exudative, active PCV in 1 eye.
• PCV is defined as choroidal neovascularization that displays occult characteristics on fluorescein angiography and polypoidal interconnecting vascular channels with saccular dilatations on indocyanine green angiography and/or fluorescein angiography.

You may not qualify if…

• Age <35 years
• Prior treatment with non-ranibizumab therapies (e.g., laser, surgery, or bevacizumab)

Where it is running

• Southeast Retina Center — Augusta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.